论文部分内容阅读
美国国立卫生研究院(NIH)和宾夕法尼亚州立大学的研究员发现,抗氧化药物Tempol通过调节肠内菌群能够降低肥胖,为开发治疗肥胖和糖尿病的药物提供了新思路。研究结果发表在《自然-通讯》期刊上。肥胖是一种严重影响人类健康的代谢性疾病,并可引发糖尿病、心血管疾病等其他代谢性疾病。美国疾病预防控制中心最新统计数据表明,2013年美国肥胖人群比例为35.7%,预计2030年将超过40%,相关的医疗费用将高达约5500亿美元。最近已有多项研究表明肥胖病人肠道中的
Researchers at the National Institutes of Health (NIH) and Pennsylvania State University found that the anti-oxidant drug Tempol can reduce obesity by regulating the intestinal flora, providing new insights into the development of drugs to treat obesity and diabetes. The findings are published in the journal Nature - Communications. Obesity is a metabolic disease that seriously affects human health and can lead to other metabolic diseases such as diabetes and cardiovascular diseases. According to the latest statistics from the CDC, the proportion of obese people in the United States was 35.7% in 2013 and is expected to exceed 40% by 2030. The related medical expenses will be as high as about 550 billion U.S. dollars. A number of recent studies have shown that obese patients are in the gut